BioSpace News Archive

A new theory by Leslie Norins, MD, PhD, founder and chief executive of Alzheimer’s Germ Quest, links Down Syndrome of children to an infectious organism which later incites Alzheimer’s disease in adults who carry it.

Today, Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ) and McMaster University (“ McMaster ”) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the Collaborative Research and Development grant, with a value of $120,000, from the Natural Sciences and Engineering Research Council of Canada (NSERC).

Taysha Gene Therapies, Inc. today announced preliminary clinical safety data for the first-generation construct in CLN7 disease.

Oncotelic Therapeutics, Inc. today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants.

Cybin Inc. is pleased to provide a year-end summary of its major milestones and key catalysts from 2021 that it believes have positioned the Company for a transformative 2022.

Vector Pharma FZCO announced today the signing of an exclusive distribution agreement with R-PHARM US of Princeton, NJ.

InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail dual-eligible seniors, announced that Maureen Hewitt, Chief Executive Officer, will be presenting virtually at the 40th Annual J.P. Morgan Healthcare Conference.

AMO Pharma Limited today announced the completion of activation of two additional clinical trial sites in Australia and New Zealand for its pivotal REACH-CDM study evaluating the efficacy and safety of the investigational therapy AMO-02.

Bone grafts are generally utilized for bone regeneration, pain relief and structure restoration for decades all over the world.

With developing technological innovations in the health care sector comprising biosensors, smartphone apps, lab-on-chip and tech tops, that offer a nearer association with the patient.